Abstract:COVID-19, a dreaded and highly contagious pandemic, is flagrantly known for its rapid prevalence across the world. Till date, none of the treatments are distinctly accessible for this life-threatening disease. Under the prevailing conditions of medical emergency, one creative strategy for the identification of novel and potential antiviral agents gaining momentum in research institutions and progressively being leveraged by pharmaceutical companies is target-based drug repositioning/repurposing. A continuous monitoring and recording of results offer an anticipation that this strategy may help to reveal new medications for viral infections. This review recapitulates the neoteric illation of COVID-19, its genomic dispensation, molecular evolution via phylogenetic assessment, drug targets, the most frequently worldwide used repurposed drugs and their therapeutic applications, and a recent update on vaccine management strategies. The available data from solidarity trials exposed that the treatment with several known drugs, viz. lopinavir-ritonavir, chloroquine, hydroxychloroquine, etc had displayed various antagonistic effects along with no impactful result in diminution of mortality rate. The drugs like remdesivir, favipiravir, and ribavirin proved to be quite safer therapeutic options for treatment against COVID-19. Similarly, dexamethasone, convalescent plasma therapy and oral administration of 2DG are expected to reduce the mortality rate of COVID-19 patients. Keywords: COVID-19, pandemic, antiviral, repurposing, vaccine, vaccination strategies

Revolutionizing viral disease treatment: phase separation and lysosome/exosome targeting as new areas and new paradigms for antiviral drug research

Revolutionizing Antiviral Therapeutics: In Silico Approaches for Emerging and Neglected RNA Viruses

The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

New perspective of small-molecule antiviral drugs development for RNA viruses

Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges

Current Progress in Antiviral Strategies.

COVID-19 Study: A New Principle Discovery

Antivirals with common targets against highly pathogenic viruses

Trends in nano-platforms for the treatment of viral infectious diseases

Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development

Anti-COVID-19 drug screening: Frontier concepts and core technologies

Multidisciplinary approaches to combat emerging viruses: diagnostics, therapeutic gene and vaccine delivery, and nanotherapeutics

Computational repurposing of drugs for viral diseases and current and future pandemics

Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology

Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary

Molecular Mechanisms and Potential Antiviral Strategies of Liquid–Liquid Phase Separation during Coronavirus Infection

COVID-19: Pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies.